IONS
Price
$70.59
Change
+$0.62 (+0.89%)
Updated
Oct 13 closing price
Capitalization
11.15B
16 days until earnings call
RARE
Price
$32.02
Change
+$0.57 (+1.81%)
Updated
Oct 13 closing price
Capitalization
3.09B
21 days until earnings call
Interact to see
Advertisement

IONS vs RARE

Header iconIONS vs RARE Comparison
Open Charts IONS vs RAREBanner chart's image
Ionis Pharmaceuticals
Price$70.59
Change+$0.62 (+0.89%)
Volume$2.62M
Capitalization11.15B
Ultragenyx Pharmaceutical
Price$32.02
Change+$0.57 (+1.81%)
Volume$1M
Capitalization3.09B
IONS vs RARE Comparison Chart in %
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IONS vs. RARE commentary
Oct 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a StrongBuy and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 14, 2025
Stock price -- (IONS: $70.59 vs. RARE: $32.02)
Brand notoriety: IONS and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IONS: 93% vs. RARE: 65%
Market capitalization -- IONS: $11.15B vs. RARE: $3.09B
IONS [@Biotechnology] is valued at $11.15B. RARE’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IONS’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • IONS’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, IONS is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IONS’s TA Score shows that 3 TA indicator(s) are bullish while RARE’s TA Score has 6 bullish TA indicator(s).

  • IONS’s TA Score: 3 bullish, 5 bearish.
  • RARE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RARE is a better buy in the short-term than IONS.

Price Growth

IONS (@Biotechnology) experienced а +2.27% price change this week, while RARE (@Biotechnology) price change was +6.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +13.62%, and the average quarterly price growth was +80.86%.

Reported Earning Dates

IONS is expected to report earnings on Oct 30, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($11.2B) has a higher market cap than RARE($3.09B). IONS YTD gains are higher at: 101.916 vs. RARE (-23.889). IONS has higher annual earnings (EBITDA): -170.69M vs. RARE (-435.33M). IONS has more cash in the bank: 2.29B vs. RARE (477M). RARE has less debt than IONS: RARE (36.3M) vs IONS (1.42B). IONS has higher revenues than RARE: IONS (944M) vs RARE (610M).
IONSRAREIONS / RARE
Capitalization11.2B3.09B363%
EBITDA-170.69M-435.33M39%
Gain YTD101.916-23.889-427%
P/E RatioN/AN/A-
Revenue944M610M155%
Total Cash2.29B477M480%
Total Debt1.42B36.3M3,912%
FUNDAMENTALS RATINGS
IONS vs RARE: Fundamental Ratings
IONS
RARE
OUTLOOK RATING
1..100
1768
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3761
P/E GROWTH RATING
1..100
61100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (64) in the Biotechnology industry is somewhat better than the same rating for IONS (100). This means that RARE’s stock grew somewhat faster than IONS’s over the last 12 months.

IONS's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for RARE (100). This means that IONS’s stock grew somewhat faster than RARE’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as RARE (100). This means that IONS’s stock grew similarly to RARE’s over the last 12 months.

IONS's Price Growth Rating (37) in the Biotechnology industry is in the same range as RARE (61). This means that IONS’s stock grew similarly to RARE’s over the last 12 months.

IONS's P/E Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for RARE (100). This means that IONS’s stock grew somewhat faster than RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IONSRARE
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 5 days ago
66%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
66%
Bearish Trend 7 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SDCI22.790.31
+1.38%
USCF SummerHaven Dyn CmdtyStgy NoK-1 ETF
PWZ24.240.16
+0.66%
Invesco California AMT-Free Muni Bd ETF
IBMT26.040.13
+0.50%
iShares iBonds Dec 2031 Term Muni Bd ETF
PCEM11.09N/A
N/A
Polen Capital Em Mkts ex-China Gr ETF
DXD22.36-0.58
-2.53%
ProShares UltraShort Dow30

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with CYTK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
+0.89%
CYTK - IONS
64%
Loosely correlated
-0.75%
MLYS - IONS
51%
Loosely correlated
+2.11%
ARWR - IONS
51%
Loosely correlated
+2.37%
MNKD - IONS
48%
Loosely correlated
+4.51%
RARE - IONS
48%
Loosely correlated
+1.81%
More